local_hospital

Śląskie Centrum Chorób Serca w Zabrzu

Address
Marii Skłodowskiej-Curie 9, 341-800 Zabrze, Poland

Śląskie Centrum Chorób Serca w Zabrzu - Cardiac Care Excellence

The Śląskie Centrum Chorób Serca (Silesian Center for Heart Diseases) in Zabrze is a distinguished cardiac research and treatment facility specializing in advanced cardiovascular interventions and preventive cardiology. The center demonstrates particular expertise in addressing complex cardiac complications associated with systemic diseases, focusing on innovative therapeutic strategies to preserve cardiac function in vulnerable patient populations.

  • Preventive cardiology and cardiomyopathy management in neuromuscular disorders
  • Beta-blocker therapy optimization and cardiac protection strategies
  • Advanced echocardiographic monitoring and left ventricular function assessment

The center's research portfolio includes groundbreaking work in Duchenne muscular dystrophy-associated cardiac complications, investigating pharmacological interventions to delay the progression of cardiomyopathy before the onset of detectable ventricular dysfunction. Through rigorous clinical trials evaluating medications such as metoprolol succinate, the facility contributes to evidence-based approaches that aim to preserve left ventricular ejection fraction and improve long-term cardiac outcomes in patients with progressive neuromuscular conditions and associated cardiac manifestations including tachycardia.

Site Overview

assignment
1
connected trial
corporate_fare
1
sponsor
science
1
IMP

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
1
Total trials linked
Low Activity
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
0
Sponsors (total)
1
Active sponsors
0

Sponsor Network

Top 10 by active trials.

No sponsors linked to active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
1
Outperforms 1% of sites
public
Therapeutic diversity
1areas
Outperforms 1% of sites
groups
Sponsor diversity
1sponsors
Outperforms 1% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Śląskie Centrum Chorób Serca w Zabrzu

Trial Sponsor Phase Status Start Date End Date
Evaluation of Metoprolol Tartrate as an Adjunct to Standard Care in Preventing Cardiomyopathy in Male Patients with Duchenne Muscular Dystrophy Aged 8-17 YearsMedical University Of GdanskPhase IIINot RecruitingJul 2021Oct 2025

IMP list

IMP Trials Status First start Last start
Metoprolol Tartrate1Unknown2021-07-122021-07-12

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.